La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Corbus Pharmaceuticals a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Corbus Pharmaceuticals..

Corbus Pharmaceuticals (NASDAQ:CRBP) Azioni, Catena delle Opzioni

CORBUS PHARMACEUTICALS HOLDI

Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.

Corbus Pharmaceuticals Holdings, Inc. - Common Stock

Corbus Pharmaceuticals Holdings Inc

News

Press Releases

Corbus Pharmaceuticals to Present at the 2025 RBC Capital Markets Global Healthcare Conference

Management

Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair

Corbus Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

Corbus Pharmaceuticals to Participate in the 3rd Annual Piper Obesity Symposium

Health Care

Corbus Pharmaceuticals Announces First Patient Dosed with its Nectin-4 Targeting ADC CRB-701 in Combination with Pembrolizumab

Corbus Pharmaceuticals Initiates Multiple Ascending Dose Portion of Phase 1 Study of Highly Peripherally Restricted CB1 Inverse Agonist CRB-913 for the Treatment of Obesity

Corbus Pharmaceuticals Announces Upcoming Presentation of Dose Expansion Phase 1/2 Clinical Data for its Nectin-4 Targeting ADC CRB-701 at the 2025 ESMO Annual Congress

Earnings

Corbus Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

FDA Grants Fast Track Designation to Corbus Pharmaceuticals' Nectin-4 Targeting ADC CRB-701 in Head and Neck Squamous Cell Carcinoma

Corbus Pharmaceuticals to Host In-Person and Virtual KOL Event at ESMO 2025

AKTX

CRBP

QURE

Achieve Life Sciences, Inc. - Common Shares

Achieve Life Sciences

Alpha Cognition

Actuate Therapeutics, Inc. - Common stock

Actuate Therapeutics

Assembly Biosciences, Inc. - Common Stock

Assembly Biosciences

Avalo Therapeutics

C4 Therapeutics

Compugen

Cardiff Oncology

Citius Oncology

Eledon Pharmaceuticals, Inc. - Common Stock

Eledon Pharmaceuticals

Elicio Therapeutics

Fate Therapeutics

Forte Biosciences

Greenwich LifeSciences, Inc. - Common stock

Greenwich LifeSciences

Genelux

Innate Pharma S.A. - American Depositary Shares

Innate Pharma

Seres Therapeutics

Nkarta

Nuvectis Pharma

Oncolytics Biotech

Protalix BioTherapeutics, Inc. (DE) Common Stock

Protalix BioTherapeutics

Pyxis Oncology

AVITA Medical

Protara Therapeutics, Inc. - Common Stock

Protara Therapeutics

Tevogen Bio Holdings

HC Wainwright & Co.

Oppenheimer

RBC Capital

Jefferies

Comments

Corbus Pharmaceuticals

Corbus Pharmaceuticals (CRBP) Opzioni

Corbus Pharmaceuticals (NASDAQ:CRBP) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO